[HTML][HTML] Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma
H Li, X Zu, J Hu, Z Xiao, Z Cai, N Gao… - Frontiers in …, 2022 - frontiersin.org
Background Though immune checkpoint inhibitors (ICIs) exhibit durable efficacy in bladder
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
[HTML][HTML] Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma
H Li, X Zu, J Hu, Z Xiao, Z Cai, N Gao… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Background Though immune checkpoint inhibitors (ICIs) exhibit durable efficacy in bladder
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
H Li, X Zu, J Hu, Z Xiao, Z Cai, N Gao… - Frontiers in …, 2022 - europepmc.org
Background Though immune checkpoint inhibitors (ICIs) exhibit durable efficacy in bladder
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma
H Li, X Zu, J Hu, Z Xiao, Z Cai… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Though immune checkpoint inhibitors (ICIs) exhibit durable efficacy in bladder
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
H Li, X Zu, J Hu, Z Xiao, Z Cai, N Gao… - Frontiers in …, 2022 - europepmc.org
Background Though immune checkpoint inhibitors (ICIs) exhibit durable efficacy in bladder
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …
carcinomas (BLCAs), there are still a large portion of patients insensitive to ICIs treatment …